{
  "docId": "019de070-ca7e-71d0-9b6d-c6cccc832e2e",
  "docSlug": "61f4be21d1a97a93f2294133e3bf0c0f",
  "documentTitle": "Bausch Health Companies | Investor Conference Presentation Deck | 10 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 4,
  "pageCount": 10,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes footnote references for licensing and S1P definition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ca7e-71d0-9b6d-c6cccc832e2e/4",
  "deckHref": "/decks/019de070-ca7e-71d0-9b6d-c6cccc832e2e",
  "deckJsonHref": "/decks/019de070-ca7e-71d0-9b6d-c6cccc832e2e.json",
  "deckAnchorHref": "/decks/019de070-ca7e-71d0-9b6d-c6cccc832e2e#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.25,
        "y": 0.97
      },
      "kind": "disclaimer",
      "text": "1. Exclusive licensing agreement with Mitsubishi Tanabe Pharma. 2. Sphingosine 1-phosphate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "314fafaa-f93b-43d7-ae0a-2d81b0379cb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.61
      },
      "kind": "list",
      "text": "Phase 2 start delayed to 2Q21 (3-arm, 336 patients, 175 sites, 12-week treatment, Mayo Score endpoint); Phase 3 start 1H24; NDA submission 2028.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19a3a679-48ac-4bfe-b5a1-fe8c7a067cab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Amiselimod is a new oral selective S1P2 receptor modulator; shows potent selectivity for S1P1; clean cardiac profile; differentiated from ozanimod (no titration, greater lymphocyte reduction, mild/moderate indication).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9baf0f1e-c9dc-4049-bd76-3eafdc48650b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.05,
        "y": 0.57
      },
      "kind": "title",
      "text": "Timeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5d53a84-f051-4616-8550-5d3c1b7fe206",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Amiselimod Capsules",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5e57c66-61a0-4730-aa9d-9232ab394a08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "Mild to Moderate Ulcerative Colitis",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4a14d67-1fde-4055-8ac9-d51f73ad594f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f7825d0a-b50f-4069-87e9-ad5856b559f7",
      "evidence": "list/bullet: Amiselimod is a new oral selective S1P2 receptor modulator; shows potent selectivity for S1P1; clean cardiac profile; differentiated from ozanimod (no titration, greater lymphocyte reduction, mild/moderate i",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "26a0baae-0573-4787-a96e-cf35b4858a66",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Amiselimod Capsules, Rifaximin Solid Soluble Dispersion (SSD) in a Tablet",
      "position": 1,
      "confidence": 0.6,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}